美國居民不適用 XM 服務。

G
G

GSK

交易方向

交易者脈動

技術摘要

小時

財經新聞

Reuters - 2天前

GSK lifts growth target for HIV business on demand for long-acting drug

UPDATE 1-GSK lifts growth target for HIV business on demand for long-acting drug Adds company outlook on dolutegravir patent expiry schedule from paragraph 11 By Ludwig Burger Sept 28 - GSK GSK.L on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection.
G
G
P
T
Reuters - 2天前

GSK lifts growth ambitions for HIV business on long-acting drug

GSK lifts growth ambitions for HIV business on long-acting drug By Ludwig Burger Sept 28 - GSK GSK.L on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection. The ViiV business, in which Pfizer PFE.L and Shionogi 4507.T hold small stakes, is a key element of a push by group CEO Emma Walmsley to improve investor confidence in the strength of GSK
G
G
P
T
Reuters - 3天前

GSK Says Wendy Becker To Join Board As Non-Executive Director

BRIEF-GSK Says Wendy Becker To Join Board As Non-Executive Director Sept 27 (Reuters) - GSK plc GSK.L : GSK PLC - DIRECTORATE CHANGE GSK - WENDY BECKER TO JOIN BOARD AS NON-EXECUTIVE DIRECTOR GSK: WENDY BECKER WILL JOIN BOARD OF COMPANY AS A NON-EXECUTIVE DIRECTOR WITH EFFECT FROM 1 OCTOBER 2023. GSK: ANNOUNCES WENDY BECKER TO JOIN BOARD AS NON-EXE
G
Reuters - 4天前

Gsk Announces Largest Private Financial Contribution To Cihr's Team Grants Initiative Addressing Threats To Canadian Lung Health

BRIEF-Gsk Announces Largest Private Financial Contribution To Cihr's Team Grants Initiative Addressing Threats To Canadian Lung Health Sept 26 (Reuters) - GSK plc GSK.L : GSK ANNOUNCES LARGEST PRIVATE FINANCIAL CONTRIBUTION TO CIHR'S TEAM GRANTS INITIATIVE ADDRESSING THREATS TO CANADIAN LUNG HEALTH GSK - INVESTING $2 MILLION IN RESEARCH TO ADDRESS
G
Reuters - 5天前

Scynexis shares tumble on recall of antifungal drug

BUZZ-Scynexis shares tumble on recall of antifungal drug ** Shares of drugmaker Scynexis Inc SCYX.O slump 32% to $2.1 in premarket trading ** Says to recall antifungal drug Brexafemme, pause studies due to potential risk of cross contamination with another compound ** Says became aware after a review by partner GSK that substances used to make beta
G

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示：您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明。